路优泰治疗早期帕金森病合并抑郁患者疗效观察.docVIP

路优泰治疗早期帕金森病合并抑郁患者疗效观察 　　【摘要】 目的 探讨路优泰在早期帕金森病伴抑郁症的临床治疗效果。方法 72例早期帕金森病伴抑郁症患者随机分为治疗组37例和对照组35例。对照组仅用抗帕金森病药物治疗， 不使用抗抑郁药。治疗组在常规治疗的基础上加用路优泰。分别在治疗前及治疗后2、4和8周通过流调用抑郁自评量表（CES-D）对患者抑郁状况进行评价。结果 治疗后， 治疗组CES-D评分明显低于对照组， 差异有统计学意义（P0.05）；两组疗效比较差异有统计学意义（P0.05）。结论 路优泰治疗早期帕金森病合并抑郁症状疗效显著， 耐受性良好， 可明显且快速改善患者的抑郁症状。 　　【关键词】 帕金森病；抑郁；路优泰 　　DOI：10.14163/j.cnki.11-5547/r.2015.19.006 　　Curative effect observation of Neurostan in the treatment of early Parkinson’s disease complicated with depression LIU Yu-mei， ZHANG Li-juan， LI Jing-xin， et al. The First Department of Neurology， Heilongjiang Provincial Hospital， Harbin 150036， China 　　【Abstract】 Objective To investigate clinical effect of Neurostan for early Parkinson’s disease complicated with depression. Methods A total of 72 early Parkinson’s disease complicated with depression patients were randomly divided into treatment group with 37 cases and control group with 35 cases. The control group received drug therapy for anti-Parkinson’s disease without anti-depression drug. The treatment group received Neurostan in addition to conventional treatment. Evaluation for depression status was made by center for epidemiologic studies depression scale （CES-D） before treatment， and in 2， 4， 8 weeks after treatment. Results After treatment， the treatment group had much lower CES-D score than the control group， and their difference had statistical significance （P0.05）. The difference of curative effects between the two groups had statistical significance （P0.05）. Conclusion Neurostan provides precise effect with good tolerance in treating early Parkinson’s disease complicated with depression. It can obviously and quickly improve depression symptoms of patients. 　　【Key words】 Parkinson’s disease； Depression； Neurostan 　　帕金森病（parkinson’s disease， PD）是一种以运动障碍为主要特征的神经系统变性病。临床上， 除运动症状外， 有相当多的患者出现神经心理异常， 尤其以伴发抑郁症状最为常见[1]， 往往容易被忽视。多数学者认为 PD 患者的抑郁情绪会影响其认知功能[2]， 不但严重影响患者的生活质量， 而且对PD患者运动障碍的恢复也有一定影响， 因此， 抗抑郁治疗对改善PD患者的整体预后具有非常重要的意义。作者应用路优泰治疗本院2010年9月～2013年5